

Making Cancer History®

Saadia A. Faiz, MD Associate Professor Pulmonary Medicine






2018 MASCC/ISOO 28-30 JUNE ANNUAL MEETING SUPPORTIVE CARE IN CANCER



Faculty Disclosure

No disclosures





Parenchymal

- Cancer-related
 - Infectious
 - Aspiration
 - Therapy-induced
 - Radiation
 - Chemotherapy
 - Immunotherapy
- Non-cancer related
 - Pulmonary edema
 - Interstitial lung disease






Parenchymal


Esophageal cancer


 Treated with 5-fluorouracil and oxaliplatin followed by radiation (50 Gy) to the esophagus

Hypoxic respiratory insufficiency












Tracheobronchial


- Hemoptysis, dyspnea, stridor
- In cases of bleeding, various airway interventions (laser, cryotherapy, argon plasma coagulation)
- Consider placement of stents








Lung cancer (IIIB) with respiratory failure 10.2013
Bronch with tumor destruction and tracheal stent
Treated with chemotherapy (carboplatin, taxol) and radiation. Repeat scan 2.2013





Pleural

Malignant pleural effusion

Paramalignant pleural effusion

Cancer and pleural effusion


Parapneumonic effusion

Other etiologies (cardiac, renal, liver dysfunction, drugs, thromboembolic)




Pleural

- Thoracentesis
 - Diagnostic and thereaputic
 - Bedside
 - Can be done in the setting of coagulopathy
 - Can be repeated if poor performance status or if underlying cause not responsive to systemic therapy
- Pleuroscopy
 - Diagnostic in unexplained exudative pleural effusion
 - Can be therapeutic with pleurodesis (agent, indwelling pleural catheter)



Indwelling Pleural Catheter (IPC)





Chest wall

Pleural space with fluid

Subcutaneous portion of catheter with polyester cuff

External portion of catheter with valve

Intrapleural portion of catheter with fenestrations

Pleural – Malignant Pleural Effusion

Local therapy

Thoracentesis

Chest tube, chemical pleurodesis
Thoracoscopic, chemical/mechanical pleurodesis
Indwelling pleural catheter

Pleuro-peritoneal shunting

Pleurectomy (decortication)


Radiation therapy



Chemotherapy Stem cell transplant

Oxygen

Palliation Opioids Hospice



Pleural - Pleurodesis

3.	
201	8
28-30 J	UNE

Procedures	Expected survival	Pleurodesis Rate, %	Advantages	28-30 JU VIENNA, AUST SUPPORTIVE CA Disadvantages EXCELL
Thoracentesis	< 3 weeks	N/A	Minimally invasive, outpatient	No pleurodesis
Indwelling pleural catheter (IPC)	> 3 weeks	42 to 58	Minimally invasive, outpatient	Indwelling chronic catheter and care, two to three times per wk drainage, infection risk, tube can clog
Tube thoracostomy	> 3 months	Approximately 70	Minimally invasive, talc pleurodesis	Inpatient hospitalization, pain at tube site, limited mobility
VATS/medical thoracoscopy	> 3 months	Approximately 80	Inspection of pleura with biopsy, talc pleurodesis	Invasive, inpatient hospitalization, tube thoracostomy after procedure

Vascular


- Pulmonary embolism
 - Anticoagulation
 - Thrombolytics
 - Catheter-directed thrombolytics
- Pulmonary hypertension
 - Sequelae of pulmonary embolism
 - Related to medications
 - Oxygen
 - Specific pulmonary vasodilators





Airway


- Obstructive lung disease
 - COPD, asthma, chronic bronchitis
 - Constrictive bronchiolitis
- Restrictive
 - Neuromuscular disease
 - Kyphoscoliosis
 - Parenchymal
- Oxygen
- Bronchodilators
- Pulmonary rehabilitation



Supportive

- Oxygen, High flow oxygen
- Non-invasive positive pressure ventilation

Medications




J Prat, NEJM 2015



After BIPAP







- Close coordination of care between pulmonologist and oncologist crucial
- Diagnose and treat potential reversible etiologies of dyspnea
- Additive therapies for symptom management and supportive care extremely helpful

Questions?





